Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Laura Moylan

Obstetrics & Gynecology Dover, DE Medical Doctor

NPI 1063496735 CMS profile 275509

640 S State St, Dover, DE 19901

Open in the dashboard

General payments

$2,483

105 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Laura Moylan of Dover, DE is reported in the CMS Open Payments database as having received $2,483 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $39 1
2023 General $166 9
2022 General $451 31
2021 General $330 22
2020 General $262 15
2019 General $1,234 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Moylan
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Laura Moylan were reported at $0. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Laura Moylan Obstetrics & Gynecology median Middle half National median
2019 $1,234 $172 $62–$391 $163
2020 $262 $94 $36–$222 $114
2021 $330 $136 $42–$369 $132
2022 $451 $160 $50–$433 $149
2023 $166 $169 $56–$423 $160
2024 $39 $152 $50–$371 $164
2025 $0 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Acessa Health Inc. $964 10 payments
  2. AbbVie, Inc. $415 27 payments
  3. Myovant Sciences Inc. $203 16 payments
  4. Evofem Biosciences, Inc. $159 11 payments
  5. TherapeuticsMD, Inc. $99 5 payments
  6. Daiichi Sankyo Inc. $95 5 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $91 6 payments
  8. Urovant Sciences Inc $46 2 payments
  9. AMAG Pharmaceuticals, Inc. $44 3 payments
  10. Pacira Pharmaceuticals Incorporated $39 1 payment
  11. Other $330 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,704 100 payments
  2. Travel and Lodging $735 2 payments
  3. Education $44 3 payments
Products named General payments · program years 2019–2024
  1. Acessa $964 10 payments
  2. MYFEMBREE $229 18 payments
  3. ORILISSA Womens Health $193 14 payments
  4. ORIAHNN $173 13 payments
  5. LO LOESTRIN FE $163 12 payments
  6. Phexxi $159 11 payments
  7. Orilissa Endocrinology $104 6 payments
  8. ANNOVERA $82 4 payments
  9. Kyleena $72 5 payments
  10. Mirena $59 4 payments
  11. Other $662 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Obstetrics & Gynecology: 65

Drug cost

$1,415

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

0%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 11 $1,415

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$2,171

Medicare's payments for the services billed

Medicare patients

16

Average age 69

Services billed

22

16 women, 0 men among their patients

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record